| Literature DB >> 25834655 |
Samuel B Low1, Edward P Allen2, Elias D Kontogiorgos3.
Abstract
OBJECTIVE: This clinical study aimed to evaluate effectiveness of a commercially available toothpaste containing potassium nitrate, sodium monoflurophosphate, and nano-hydroxyapatite as well as antioxidants phloretin, ferulic acid and silymarin in reducing dental hypersensitivity in adults.Entities:
Keywords: Antioxidants; dentin hypersensitivity; hydroxyapatite; polyphenol
Year: 2015 PMID: 25834655 PMCID: PMC4378071 DOI: 10.2174/1874364101509010092
Source DB: PubMed Journal: Open Dent J ISSN: 1874-2106
Patient data included in this study according to gen-der, age and dental sensitivity.
| Sample Size (N) | 60 patients | 100.0% |
|---|---|---|
| Gender | 47 females | 78.3% |
| AGE 18 - 25 | 7 patients | 12.1% |
| AGE 26 - 35 | 7 patients | 12.1% |
| AGE 36 - 45 | 11 patients | 19.0% |
| AGE 46 - 55 | 11 patients | 19.0% |
| AGE 56 - 65 | 10 patients | 17.2% |
| AGE 66 - 75 | 11 patients | 19.0% |
| AGE 75 - 82 | 1 patients | 1.7% |
| SENSITIVE DUE TO TOOTH EXPOSURE | 32 patients | 53.3% |
| SENSITIVE DUE TO TEETH WHITENING | 9 patients | 15.0% |
| SENSTIVITY DUE TO CHEMO/RADIATION | 0 patients | 0.0% |
| SENSITIVITY DUE TO OTHER | 10 patients | 16.7% |
| SENSITIVITY DUE TO | 9 patients | 15.0% |
Repeated-measures MANOVA with time as within-subject factor and gender as between-subject factor (P ≤.05) for all questions.
| Source | F Value* | Hypothesis df | Error df | Significance |
|---|---|---|---|---|
| Time | 10.512 | 10.000 | 168.000 | P≤.001 |
| Time * Gender | 0.660 | 10.000 | 18.000 | P=.760 |
F-values are based on Wilk's Lambda statistics.
Repeated-measures MANOVA with time as within-subject factor and gender as between-subject factor (P ≤.05) according to each question.
| Source | Question | Type III Sum of Squares | df | Mean Square | F | Significance |
|---|---|---|---|---|---|---|
| Time | Q1 | 163.729 | 2 | 81.864 | 54.474 | P≤.001 |
| Q2 | 71.728 | 2 | 35.864 | 22.709 | P≤.001 | |
| Q3 | 133.560 | 2 | 66.780 | 32.884 | P≤.001 | |
| Q4 | 98.491 | 2 | 49.245 | 27.137 | P≤.001 | |
| Q5 | 74.357 | 2 | 37.178 | 8.634 | P≤.001 | |
| Time*Gender | Q1 | 3.925 | 2 | 1.963 | 1.306 | P=.276 |
| Q2 | 2.501 | 2 | 1.250 | 0.792 | P=.456 | |
| Q3 | 1.244 | 2 | 0.622 | 0.306 | P=.737 | |
| Q4 | 1.456 | 2 | 0.728 | 0.401 | P=.671 | |
| Q5 | 8.462 | 2 | 4.231 | 0.983 | P=.378 | |
| Error (Time) | Q1 | 132.249 | 88 | 1.503 | ||
| Q2 | 138.980 | 88 | 1.579 | |||
| Q3 | 178.707 | 88 | 2.031 | |||
| Q4 | 159.696 | 88 | 1.815 | |||
| Q5 | 378.925 | 88 | 4.306 |
Post-hoc analysis of the data (mean ± standard deviation) for every question according to time. Used Sidak’s adjustment for multiple comparisons (P≤.05).
| Time | Question 1 | Question 2 | Question 3 | Question 4 | Question 5 |
|---|---|---|---|---|---|
| Baseline | 5.7 (±1.8) | 4.3 (±1.8) | 5.9 (±1.7) | 4.6 (±2.0) | 5.6 (±2.6) |
| Day 2 | 3.6 (±2.2)a | 3.3 (±2.1)a | 4.5 (±2.1)a | 3.2 (±2.3)a | 4.9 (±2.8) |
| Week 2 | 2.5 (±1.9)b,c | 2.2 (±1.8)b,c | 3.0 (±2.1)b,c | 2.1 (±1.8)b,c | 3.5 (±2.8)b,c |
Indicates statistical difference between Baseline and Day 2
Indicates statistical difference between Baseline and Week 2
Indicates statistical difference between Day 2 and Week 2
Number of patients that showed improvement (%) by at least 10% on the VAS according to question.
| Question 1 | Question 2 | Question 3 | Question 4 | Question 5 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Time | Patients | Improvement(%)* | Patients | Improvement | Patients | Improvement | Patients | Improvement | Patients | Improvement |
| Baseline | 60 | - | 60 | - | 60 | - | 60 | - | 60 | - |
| Day2 | 39(65%) | 50.3 (±26.3) | 27(45%) | 51.6 (±28.6) | 32(53%) | 45.0 (±28.4) | 32(52%) | 52.5 (±28.2) | 25(42%) | 49.9 (±30.3) |
| Week2 | 47(78%) | 59.4 (±24.9) | 41(68%) | 58.6 (±25.3) | 43(72%) | 58.8 (±25.3) | 44(73%) | 59.9 (±23.9) | 36(60%) | 60.1 (±27.4) |
Improvement (%) values are presented as Mean (±Standard Deviation)
Number of patients that answered >5 at Baseline and showed improvement (%) by at least 10% on the VAS according to question.
| Question 1 | Question 2 | Question 3 | Question 4 | Question 5 | ||||||
| Time | Patients | Improvement(%)* | Patients | Improvement | Patients | Improvement | Patients | Improvement | Patients | Improvement |
| Baseline | 38 | - | 19 | - | 46 | - | 29 | - | 30 | - |
| Day2 | 29(76%) | 51.1 (±24.9) | 14(74%) | 43.0 (±26.2) | 24(52%) | 46.4 (±26.0) | 19(66%) | 51.4 (±26.8) | 17(57%) | 49.1 (±27.8) |
| Week2 | 32(84%) | 57.9 (±24.3) | 16(84%) | 50.6 (±19.6) | 34(74%) | 55.4 (±25.6) | 24(83%) | 60.3 (±25.3) | 21(70%) | 62.2 (±28.7) |
Improvement (%) values are presented as Mean (±Standard Deviation)